Literature DB >> 15699154

Identification of murine poxvirus-specific CD8+ CTL epitopes with distinct functional profiles.

Anuja Mathew1, Masanori Terajima, Kim West, Sharone Green, Alan L Rothman, Francis A Ennis, Jeffrey S Kennedy.   

Abstract

Murine T cell epitopes against vaccinia virus (VV) have not been characterized to date in part due to the large and complex genome of VV. We have identified and characterized two CD8+ T cell epitopes on the A47L (modified VV Ankara strain (MVA)-029) and J6R (MVA-043) proteins of VV that are Db and Kb restricted, respectively. Following i.p. immunization with VV New York City Board of Health (NYCBH) strain, MVA-029 peptide-stimulated splenocytes secreted IFN-gamma from 7 days to 7 mo postimmunization, and virus-stimulated effectors were also able to lyse MVA-029-pulsed target cells at the same time points. In contrast, MVA-043 peptide-stimulated splenocytes secreted very low levels of IFN-gamma only at day 7 but maintained the ability to lyse target cells up to 2 mo postimmunization. Both MVA-029 and MVA-043 peptide-stimulated lymph node cells degranulated similarly as assessed by Ag-induced CD107 expression. T cell responses to whole-virus stimulation remained robust and steady during the acute and memory T cell response to VV. Identification of T cell epitopes on VV will enable further studies to increase our understanding of the role of CD8+ T cells in VV infection and assist in the design of new protective strategies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15699154     DOI: 10.4049/jimmunol.174.4.2212

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Sequential immunization with heterologous chimeric flaviviruses induces broad-spectrum cross-reactive CD8+ T cell responses.

Authors:  Rekha Singh; Alan L Rothman; James Potts; Farshad Guirakhoo; Francis A Ennis; Sharone Green
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

Review 2.  Clinical development of Listeria monocytogenes-based immunotherapies.

Authors:  Dung T Le; Thomas W Dubenksy; Dirk G Brockstedt
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

Review 3.  Initiation of primary anti-vaccinia virus immunity in vivo.

Authors:  Matthew A Fischer; Christopher C Norbury
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

4.  Dissociation between epitope hierarchy and immunoprevalence in CD8 responses to vaccinia virus western reserve.

Authors:  Carla Oseroff; Bjoern Peters; Valerie Pasquetto; Magdalini Moutaftsi; John Sidney; Vijay Panchanathan; David C Tscharke; Bernard Maillere; Howard Grey; Alessandro Sette
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

5.  Qualitative and quantitative characteristics of rotavirus-specific CD8 T cells vary depending on the route of infection.

Authors:  Janina Q Jiang; Xiao-Song He; Ningguo Feng; Harry B Greenberg
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

6.  Accurate mass precursor ion data and tandem mass spectrometry identify a class I human leukocyte antigen A*0201-presented peptide originating from vaccinia virus.

Authors:  Kenneth L Johnson; Inna G Ovsyannikova; Benjamin J Madden; Gregory A Poland; David C Muddiman
Journal:  J Am Soc Mass Spectrom       Date:  2005-09-26       Impact factor: 3.109

7.  Altered effector functions of virus-specific and virus cross-reactive CD8+ T cells in mice immunized with related flaviviruses.

Authors:  Derek W Trobaugh; Liyan Yang; Francis A Ennis; Sharone Green
Journal:  Eur J Immunol       Date:  2010-05       Impact factor: 5.532

8.  Protection against vaccinia virus challenge by CD8 memory T cells resolved by molecular mimicry.

Authors:  Markus Cornberg; Brian S Sheridan; Frances M Saccoccio; Michael A Brehm; Liisa K Selin
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

Review 9.  Smallpox vaccines for biodefense.

Authors:  Richard B Kennedy; Inna Ovsyannikova; Gregory A Poland
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

10.  Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination.

Authors:  Douglas W Grosenbach; Robert Jordan; David S King; Aklile Berhanu; Travis K Warren; Dana L Kirkwood-Watts; Shanthakumar Tyavanagimatt; Ying Tan; Rebecca L Wilson; Kevin F Jones; Dennis E Hruby
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.